Abstract:Enterovirus A71 (EV-A71) is a non-polio neurotropic enterovirus with pandemic potential. There are no antiviral agents approved to prevent or treat EV-A71 infections. We here report on the molecular mechanism by which a novel class of tryptophan dendrimers inhibits (at low nanomolar to high picomolar concentration) EV-A71 replication <em>in vitro</em>. A lead compound in the series (MADAL385) prevents binding and internalization of the virus but does not, unlike classical capsid binders, stabilize the particle. By means of resistance selection, reverse genetics and cryo-EM, we map the binding region of MADAL385 to the 5-fold vertex of the viral capsid and demonstrate that a single molecule binds to each vertex. By interacting with this region, MADAL385 prevents the interaction of the virus with its cellular (co-)receptors PSGL1 and heparan sulfate, thereby blocking the attachment of EV-A71 to the host cells.Enterovirus A71 (EV-A71) is the virus responsible for most of the severe forms of hand, foot and mouth disease (HFMD) associated with neurological involvement and mortality in young children under the age of 5. Seasonal outbreaks of HFMD -with a 2–3 years epidemic cycle- are recurring around the world, especially in the Asia-Pacific region. To date, no antiviral agent has been approved for the treatment of EV-A71 infections. Here, we report on a recently uncovered class of tryptophan dendrimers with an extraordinary antiviral activity <em>in vitro</em> against circulating EV-A71 clinical isolates. Mode of action studies revealed that this class of compounds target the 5-fold vertex of EV-A71, in turn blocking (co)receptor binding. Our finding may open an entirely novel line of research and largely aid in anti-enterovirus drug development.

Discovery of Aminothiazole Derivatives As Novel Human Enterovirus A71 Capsid Protein Inhibitors

Identification of a novel binding inhibitor that blocks the interaction between hSCARB2 and VP1 of enterovirus 71

Discovery of Novel Andrographolide Derivatives as Antiviral Inhibitors against Human Enterovirus A71

Design, Synthesis, and Evaluation of Novel Enterovirus 71 Inhibitors As Therapeutic Drug Leads for the Treatment of Human Hand, Foot, and Mouth Disease.

Inhibition of Enterovirus 71 Replication by an Α-Hydroxy-nitrile Derivative NK-1.9k

Discovery of 3-Benzyl-1,3-benzoxazine-2,4-dione Analogues As Allosteric Mitogen-Activated Kinase Kinase (MEK) Inhibitors and Anti-Enterovirus 71 (EV71) Agents.

New Potent EV-A71 Antivirals Targeting Capsid.

Viral engagement with host receptors blocked by a novel class of tryptophan dendrimers that targets the 5-fold-axis of the enterovirus-A71 capsid

Studies on Inhibition of Proliferation of Enterovirus-71 by Compound YZ-LY-0

An adenosine nucleoside analogue NITD008 inhibits EV71 proliferation

Computational and experimental studies of salvianolic acid A targets 3C protease to inhibit enterovirus 71 infection

Discovery of Potent and Broad-Spectrum Pyrazolopyridine-Containing Antivirals against Enteroviruses D68, A71, and Coxsackievirus B3 by Targeting the Viral 2C Protein

Identification, synthesis and pharmacological evaluation of novel anti-EV71 agents via cyclophilin A inhibition

Enterovirus A71 antivirals: Past, present, and future

In vitro discovery of a therapeutic lead for HFMD from a library screen of rocaglates/aglains

Cathelicidin peptide analogues inhibit EV71 infection through blocking viral entry and uncoating

Chemoproteomics enables identification of coatomer subunit zeta-1 targeted by a small molecule for enterovirus A71 inhibition

Biochemical Characterization of Recombinant Enterovirus 71 3C Protease with Fluorogenic Model Peptide Substrates and Development of a Biochemical Assay

Optimize the interactions at S4 with efficient inhibitors targeting 3C proteinase from enterovirus 71

In Vitro and in Vivo Protection Against Enterovirus 71 by an Antisense Phosphorothioate Oligonucleotide

Antiviral activity of the HSP90 inhibitor VER-50589 against enterovirus 71